Association of the Choline Acetyltransferase Gene with Responsiveness to Acetylcholinesterase Inhibitors in Alzheimer's Disease
The pathology of the brain cholinergic system is prominent in AD and AChEI drugs are widely used. Thus, the cholinergic system is a logical target for pharmacogenomic studies. There have been several studies on possible associations between genetic polymorphisms of cholinergicrelated genes and the therapeutic effect of AChEIs [10, 11] . However, there are limitations as follows in those previous studies. First, the results are inconsistent. Second, the selection of SNPs was limited, so the entire candidate gene region was not covered. Moreover, ethnic heterogeneity was not explored in these studies. In the present study we have examined the polymorphic variations of the genes encoding 3 enzymes involved in the synthesis, transport, and metabolism of acetylcholine in the cholinergic system ( • ▶ Fig. 1 ) [11, 12] . Choline acetyltransferase (ChAT) encoded by the gene CHAT synthesizes acetylcholine, using choline and acetyl-CoA as substrates [11] . The choline transporter (ChT) catalyzes the uptake of choline from the extracellular space to the neuronal cytoplasm, and is encoded by SLC5A7 [12] . Acetylcholine esterase (AChE) is Introduction ▼ Dementia is a progressive neurodegenerative disease with a rising prevalence and societal burden [1, 2] . Alzheimer's disease (AD) is the most common form in dementia and it accounts for 60-70 % of all cases [3] . AD is associated with widespread degeneration of cholinergic neurons, and acetylcholinesterase inhibitor (AChEI) drugs are approved for symptomatic treatment, with the aim of restoring the cholinergic deficit [4] . However, therapeutic response rates vary from 40-70 % [5] . If the response to the drug initially selected is insufficient, a change of drugs can be considered. However, the recognition of non-response requires prolonged observation. Thus, an ability to predict response early in the course of AD is an important therapeutic objective. One promising approach is pharmacogenomics [6] . Several preliminary pharmacogenomic studies [7, 8] have reported that the clinical response to donepezil is highest in carriers of the APOE epsilon4 allele, although a recent large study obtained a negative result [9] . also aimed to assess in our Asian (Korean) population the replicability of previous reports in Caucasians [10, 11] . The hypothesis of this exploratory study is that SNPs of genes involved in the synthesis and movement of acetylcholine may affect the response of AChEIs in AD.
Patients and Methods

▼ Subjects
Subjects were 158 patients diagnosed with AD from the Clinical Trial Program in the Geropsychiatry Clinic at the Samsung Medical Center. All were of unrelated Korean ancestry. Patients were registered between November 2001 and January 2012. Subjects were eligible for this clinical trial only if they satisfied all following criteria: All patients were diagnosed as AD or probable AD according to the standards of the NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association) [13] ; They had a score of 26 or less in the Korean version of the Mini-Mental State Examination (K-MMSE) [14] ; They had a history of cognitive decline which was gradual in onset and progressive for more than 6 months; they had a reliable caregiver who helped them to take their medication, participate in the assessment, and provide ongoing information about them [13] . Patients were excluded if any of the following conditions was present: other neurodegenerative diseases except AD (i. e., Parkinson's disease or Huntington's disease), psychiatric disorder or severe behavioral disturbances requiring psychotropic medications, cerebral injuries induced by trauma, hypoxia, and/or ischemia, clinically active cerebrovascular disease, medical history of seizure disorder, and other physical conditions requiring acute treatments. All subjects underwent brain magnetic resonance imaging (MRI), neurological evaluation, and routine laboratory tests prior to this clinical trial in order to screen for other possible causes of dementia. The Institutional Review Board (IRB) at Samsung Medical Center approved the protocol. Written informed consent was obtained from both caregiver and patient. The study is registered (NCT01198093) in ClinicalTrials.gov.
Procedures
Subjects were assigned to receive monotherapy for 26 weeks with an acetylcholinesterase inhibitor (donepezil, galantamine or rivastigmine) as determined by a clinician. In this semi-naturalistic clinical trial, the choice of drug was based on the antici-pated side effects in at-risk individuals and on current clinical practice guidelines. Donepezil was administered to 84 patients, galantamine to 52 patients and rivastigmine to 22 patients. Doses were titrated into the usual range based on tolerability and side effects. All subjects were assessed in clinic visits after 1 week and 4 weeks on drug to adjust the dosage and evaluate adverse events. Psychotropic medications except acetylcholinesterase inhibitors were not allowed with one exception. Benzodiazepines could be used only as a short-term adjunctive for insomnia. If the subjects did not show any significant changes or serious adverse events, the interval for clinic visits was increased to 13 weeks. Experienced geriatric psychiatrists performed the assessment at each visit for clinical review of cognitive status, to examine physical and neurological status, and to review adverse events. Vital sign checks, physical examinations, laboratory tests including complete blood counts, blood chemistry profiles, vitamin B12/folate levels, syphilis serology, thyroid function tests, and ECG at baseline were carried out in all subjects.
Selection of SNP markers and genotyping
These SNPs were genotyped using the MassARRAY system (Sequenom, Inc., San Diego, Calif). 25 SNPs were discovered and selected as candidate genes with the computer program Tagger [15] with criteria of r 2 > 0.65 and minor allele frequency > 0.05 in combined Asian population (JPT/HCB). 21 for CHAT, 3 for SLC5A7 and one for ACHE were genotyped. The total missing genotype counts were 50 (total call rate: 98.7 %), these genotyping data were not included in the SNP association analyses. All investigators and raters were blinded to the results of genotyping throughout the study. The laboratory worker who performed the genotyping was blind to clinical data of the subjects. The organization and selected SNP locations of CHAT gene are shown in • ▶ Fig. 2 . There were no significant differences in genotype distribution of the 25 SNPs according to drug choice.
Measures
The response rate was assessed and compared at 26 weeks of treatment. Response was defined as no change (i. e., no deterioration) or improvement on the score of the Korean version of the Mini-Mental State Examination (K-MMSE) [16, 17] . Global severity of disease was assessed according to the Clinical Dementia Rating (CDR) [18] . These research assessments of cognitive outcome were performed by a single, trained rater.
Data analysis
Continuous variables were presented as mean ± standard deviation (SD) or as median and interquartile range. Categorical variables were summarized as frequencies and proportions. Wilcoxon rank-sum test or Student's t test was performed to compare continuous variables between 2 groups according to the normality of the distribution. The association of categorical variables was determined based on the chi-squared test in all subjects. We assessed the associations between each SNP and responsiveness by using the exact Cochran-Armitage test for trend (a genotypic trend model) [19] . Chi-squared testing was used to examine deviation from Hardy-Weinberg equilibrium [20] . The four-gamete rule by Haploview was used to check linkage disequilibrium (LD) structure [21] . Phasing haplotypes were conducted using PHASE 2.1.1 for each of the haplotype blocks individually [22] . The exact Cochran-Armitage test for a trend was used to examine the associations between a haplotype For the significance of association of a SNP or haplotype allele, the false discovery rate (FDR) control was used to correct each P-value [23] . The associated SNPs and haplotype alleles were entered into a multiple logistic regression model to evaluate the impact of each genetic variable on response, adjusting for other variables. In this model, the genetic variable represented the minor allele count for a subject (0, 1 or 2) and the dependent variable represented the treatment outcome (1 = response and 0 = nonresponse). Results were considered as significant with a threshold of P < 0.05. All statistical tests were performed using SAS 9.1 (SAS Institute, Inc., Cary, North Carolina).
Results
▼
Subject characteristics
Clinical and demographic characteristics are shown in • ▶ Table 1 .
Mean age of the subjects was 72.66 (SD = 8.31) years and most were in the early stage of Alzheimer's disease. The rate of response to acetylcholinesterase inhibitors was 102 of 158 (64.6 %). There was no significant difference between responders and non-responders with respect to gender, age, education level and baseline global severity (CDR). The rate of response was not affected by choice of drug (donepezil, galantamine and rivastigmine). However, there was a marginally significant difference rs733722  rs1880676  rs3810950  rs4838391  rs4838392  rs12246528  rs11101187  rs2177370  rs3793790  rs3793791  rs2177369  rs12266458  rs1917818  rs11101192  rs11101193  rs10776586  rs12264845  rs7076926  rs7094421  rs3793798  rs3793800  rs3793801  rs3793797  rs7094248 SNPs included in this study between responders and non-responders in baseline K-MMSE score (P = 0.04).
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SNP association analysis with responder of acetylcholinesterase inhibitors
The results of SNP association analysis are shown in • ▶ Table 2 .
The observed genotype frequencies in each case fitted the ones expected according to the Hardy-Weinberg equilibrium, except one SNP, rs12246528 (P = 2.80 × 10 − 24 ). However, we did not exclude this SNP, because this pharmacogenetic study was conducted in AD patients and did not have a normal control group [19, 24] . Moreover, 2 adjacent SNPs (rs2177370 and rs3793790) were significantly associated with response. The rs2177370 in the intronic region of CHAT gene was significantly associated with response (uncorrected P = 0.0025, FDR controlled P = 0.026). The rs3793790 located in the same intron of the rs2177370 showed a significant association with responsiveness (uncorrected P = 0.0024, FDR controlled P = 0.026). These associations were preserved after controlling for gender, age, education year, drug and baseline K-MMSE score (for rs2177370, P = 0.0065, odds ratio = 2.45, 95 % confidence interval = 1.28-4.68; for rs3793790, P = 0.0039, odds ratio = 2.73, 95 % confidence interval = 1.38-5.38).
Haplotype association analysis with responder of acetylcholinesterase inhibitors
We discovered 4 haplotype blocks in the CHAT gene ( • ▶ Fig. 3) .
Among the 13 haplotype allele, 2 alleles in block 2 that included rs2177370 had significant associations with response (for haplotype CC, uncorrected P = 0.004, FDR controlled P = 0.023; for haplotype CT, uncorrected P = 0.003, FDR controlled P = 0.023). These haplotypes were also associated with response after controlling for gender, age, education year, drug and baseline K-MMSE score (for haplotype CC, P = 0.006, odds ratio = 0.44, 95 % confidence interval = 0.24-0.79; for haplotype CT, P = 0.006, odds ratio = 2.47, 95 % confidence interval = 1.29-4.72). However, no haplotype blocks were found to be significantly associated with response in the SLC5A7 gene or the ACHE gene ( • ▶ Table 3 ).
Discussion
▼
In this study we assessed 25 SNPs of 3 cholinergic system genes (CHAT, SLC5A7 and ACHE) for association with response to AChEI drugs in AD. We found that 2 SNPs in the intronic region of CHAT, rs2177370 and rs3793790 had a significant association with drug response. Haplotype association analysis which was additionally performed showed that block 2 including rs2177370 among 4 haplotype blocks of the CHAT gene had a significant association with drug response. However, the ACHE and SLC5A7 genes did not contain SNPs or haplotypes that were significantly associated with response. From this we conclude that the brain's ability to synthesize ACh in AD is a critical factor for response to AChEIs, whereas transport and inactivation of the transmitter are less important factors. The association of CHAT gene polymorphisms with response is consistent with a previous study [10] , but the association with CHAT rs2177370 has not been previously described. In one previous study CHAT rs733722 had a significant association with AChEI drug response in AD patients [10] . In a second study, no association of CHAT rs2177369 with response was reported [11] .
The CHAT gene has also been studied for association with AD onset [11] , AD risk factor [25] , and depression in AD [25] ( • ▶ Fig. 2) . Although the significantly associated SNPs in our study differ from those in previous studies, these other results suggest convergent evidence for the importance of the CHAT gene as a significant gene marker that affects the response of AChEIs. Our results call attention to the role of ChAT in the synthesis of acetylcholine and to the mechanism of action of AChEIs in patients with AD.
Acetylcholinesterase inhibitors are drugs that inhibit the acetylcholinesterase enzyme from breaking down acetylcholine, thereby increasing both the level and duration of action of the neurotransmitter acetylcholine [26] . However, AChEI drugs depend for their efficacy on an adequate synthesis of ACh. When ACh synthesis already is impaired by degeneration of cholinergic neurons in AD, then a genetically determined relatively high synthesis capacity in the remaining neurons would be expected to favor response to AChEI drugs, and vice versa. We might infer that haplotype CC, with an odds ratio for response of 0.44, is associated with a relatively reduced rate of ACh synthesis, whereas haplotype CT, with an OR of 2.47, is associated with a relatively high rate of ACh synthesis. Additional studies are needed to establish the functional direction of influence that rs2177370 and rs3793790 exert on the activity of CHAT.
We did not confirm the report of Scacchi et al. that the ACHE rs2571598 had a significant association with drug response in AD patients treated with rivastigmine [11] . We found no association between the ACHE gene and response to AChEI drugs. The discrepancies between our study and Scacchi's may due to differences of SNP selection, ethnicity and the genetic models adopted. In a previous study examining the CHAT gene, rs3810950 had a significant association with both depression [25] and disease progression [27] in AD. However, there was no association with drug response in this study. Because both comorbid depression and disease stage can influence cognitive function in AD, these factors will need to be considered in future pharmacogenetic studies. We conducted this study in Korean patients. In our previous pharmacogenetic study of the serotonin transporter in patients with depression, conflicting results were reported according to ethnicity (Caucasian, Asian) [28] . Most of the existing genetic studies for drug response in AD patients have been limited to Caucasian populations. Thus, replication studies in different ethnic populations will be required. Our study is the first haplotype association study of response of AChEIs and found that haplotype blocks located on CHAT may affect response in both favorable and unfavorable directions. A possible limitation or a potential advantage in this study was the use of 3 members of the AChEI drug class. On the one hand we lack statistical power to examine SNP associations with response to individual drugs. On the other hand, by using all the common members of the AChEI class our results may be generalizable to the clinical setting.
